FT825
HER2-positive Solid Tumors
Phase 1Active
Key Facts
About Fate Therapeutics
Fate Therapeutics is dedicated to transforming patient lives with autoimmune diseases and cancer through its proprietary iPSC platform, which generates 'off-the-shelf' cell therapies. The company's mission is to make cell therapy delivery routine and accessible by developing multiplexed-engineered cell product candidates that incorporate novel synthetic controls of cell function. Its pipeline includes several clinical-stage candidates, such as FT819, FT825, FT836, FT839, and FT522, targeting both oncology and autoimmune indications. Fate operates as a public company, leveraging strategic collaborations to advance its science and clinical development.
View full company profile